Negative on the sarcasm. He is buying shares when we ipo we will...

First 46 Last

Share
Profile

Follow
inapinchpenny

335 Posts.

29/06/15

09:52

Post #: 15546338
Share

Originally posted by DONMAN ↑

I think you'll find Dirk is being sarcastic.

The IPO news is so-so. I'm still getting my head around it ATM.

The big question is what will be the price for 50% of the company and when is the best time to sell it?

As Pannobhaso's blog states "I was not too impressed as there is nothing new in the prospectus. This means that there is a 50% dilution with no new value being identified"

That's correct so to me it does not come across as a very compelling public offer. The prospectus in it's
current form can consequently be viewed by new American investors as a life boat for the company if TT-034 doesn't work in it's current form. So, who would risk buying into that?

However the below statement suggest to me that the board could price this IPO after they "expect to receive efficacy data in the fourth quarter of 2015"

"The amounts and timing of any expenditures may vary from expectations depending upon numerous factors, including the progress of the company's research and development efforts, the progress of its clinical trials and it's operating costs"

If the board wait still after efficacy the ASX price could/should be north of $5 which would result in a NASDAQ listing north of $77 a share and a company that had a very very compelling offer being:

A one-shot cure for HCV together with a new platform technology for treating human diseases etc.

Expand

Negative on the sarcasm. He is buying shares when we ipo we will start blogging again.

BLT Price at posting: 71.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals